用于癌症诊断的 CT/MRI Theranostics 抗体共轭物:最新趋势和进展综述

IF 3.5 Q2 CHEMISTRY, ANALYTICAL
Saba Abaei, Ali Tarighatnia, Asghar Mesbahi and Ayuob Aghanejad
{"title":"用于癌症诊断的 CT/MRI Theranostics 抗体共轭物:最新趋势和进展综述","authors":"Saba Abaei, Ali Tarighatnia, Asghar Mesbahi and Ayuob Aghanejad","doi":"10.1039/D4SD00132J","DOIUrl":null,"url":null,"abstract":"<p >The constant need for cancer diagnosis in the early stages drives the development of contrast agents and imaging methods. Imaging agents have important roles in monitoring the progression and metastasis of cancers. Antibodies as biomolecules in conjugation with nanoparticles, radioisotopes, and drugs have been used as biomarkers for the early diagnosis/therapy of cancers due to their serum stability, affinity, and specificity. While antibodies are commonly used as nuclear medicine biomarkers, antibody-based contrast agent platforms have recently gained attention in X-ray computed tomography (CT) and magnetic resonance imaging (MRI). The developing antibody-based contrast agents have revolutionized cancer imaging techniques, particularly through MRI. Despite the promising advancements, some challenges and limitations need to be addressed for the extensive applications of these agents. Ongoing research is focused on overcoming challenges and limitations to enhance the efficiency and accuracy of these imaging methods. With continued advancements, antibody-based contrast agents hold immense potential in the early diagnosis and treatment of cancer. In this review, we summarize and categorize the recent progress in targeted imaging using antibody-based contrast agents by MRI and CT modalities.</p>","PeriodicalId":74786,"journal":{"name":"Sensors & diagnostics","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2024/sd/d4sd00132j?page=search","citationCount":"0","resultStr":"{\"title\":\"Antibody conjugates as CT/MRI Theranostics for diagnosis of cancers: a review of recent trends and advances\",\"authors\":\"Saba Abaei, Ali Tarighatnia, Asghar Mesbahi and Ayuob Aghanejad\",\"doi\":\"10.1039/D4SD00132J\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >The constant need for cancer diagnosis in the early stages drives the development of contrast agents and imaging methods. Imaging agents have important roles in monitoring the progression and metastasis of cancers. Antibodies as biomolecules in conjugation with nanoparticles, radioisotopes, and drugs have been used as biomarkers for the early diagnosis/therapy of cancers due to their serum stability, affinity, and specificity. While antibodies are commonly used as nuclear medicine biomarkers, antibody-based contrast agent platforms have recently gained attention in X-ray computed tomography (CT) and magnetic resonance imaging (MRI). The developing antibody-based contrast agents have revolutionized cancer imaging techniques, particularly through MRI. Despite the promising advancements, some challenges and limitations need to be addressed for the extensive applications of these agents. Ongoing research is focused on overcoming challenges and limitations to enhance the efficiency and accuracy of these imaging methods. With continued advancements, antibody-based contrast agents hold immense potential in the early diagnosis and treatment of cancer. In this review, we summarize and categorize the recent progress in targeted imaging using antibody-based contrast agents by MRI and CT modalities.</p>\",\"PeriodicalId\":74786,\"journal\":{\"name\":\"Sensors & diagnostics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.rsc.org/en/content/articlepdf/2024/sd/d4sd00132j?page=search\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sensors & diagnostics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2024/sd/d4sd00132j\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, ANALYTICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sensors & diagnostics","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/sd/d4sd00132j","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0

摘要

对癌症早期诊断的持续需求推动了造影剂和成像方法的发展。成像剂在监测癌症进展和转移方面发挥着重要作用。抗体作为与纳米粒子、放射性同位素和药物结合的生物大分子,由于其血清稳定性、亲和力和特异性,已被用作癌症早期诊断/治疗的生物标记物。虽然抗体通常被用作核医学生物标记物,但基于抗体的造影剂平台最近在 X 射线计算机断层扫描(CT)和磁共振成像(MRI)领域也受到了关注。抗体造影剂的发展彻底改变了癌症成像技术,尤其是核磁共振成像技术。尽管取得了令人鼓舞的进展,但要广泛应用这些制剂,还需要应对一些挑战和限制。目前的研究重点是克服挑战和限制,以提高这些成像方法的效率和准确性。随着技术的不断进步,抗体造影剂在癌症的早期诊断和治疗方面具有巨大的潜力。在这篇综述中,我们总结并归类了通过核磁共振成像和 CT 模式使用抗体造影剂进行靶向成像的最新进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Antibody conjugates as CT/MRI Theranostics for diagnosis of cancers: a review of recent trends and advances

Antibody conjugates as CT/MRI Theranostics for diagnosis of cancers: a review of recent trends and advances

The constant need for cancer diagnosis in the early stages drives the development of contrast agents and imaging methods. Imaging agents have important roles in monitoring the progression and metastasis of cancers. Antibodies as biomolecules in conjugation with nanoparticles, radioisotopes, and drugs have been used as biomarkers for the early diagnosis/therapy of cancers due to their serum stability, affinity, and specificity. While antibodies are commonly used as nuclear medicine biomarkers, antibody-based contrast agent platforms have recently gained attention in X-ray computed tomography (CT) and magnetic resonance imaging (MRI). The developing antibody-based contrast agents have revolutionized cancer imaging techniques, particularly through MRI. Despite the promising advancements, some challenges and limitations need to be addressed for the extensive applications of these agents. Ongoing research is focused on overcoming challenges and limitations to enhance the efficiency and accuracy of these imaging methods. With continued advancements, antibody-based contrast agents hold immense potential in the early diagnosis and treatment of cancer. In this review, we summarize and categorize the recent progress in targeted imaging using antibody-based contrast agents by MRI and CT modalities.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信